alcohol antagonist devoid of discernible side effects a possibility. It will be interesting to see whether the actions of Ro15-4513 in reversing alcohol's sedative actions in primates as reported by Miczek and Weerts are observed with other inverse agonists. Finally, Miczek and Weerts confirm our findings in rats that Ro15-4513 will "partially restore motor activity that was impaired by large alcohol doses (1.5 to 3.0 grams per kilogram orally)" and extend these observations to squirrel monkeys. We would like to emphasize that in our studies in rats Ro15-4513 is more potent at blocking the intoxication syndrome (that is, when administered before alcohol) than in reversing it, since the latter requires higher doses of drug (*10*). Ro15-4513 promises to remain an important tool in alcohol research as we and others attempt to develop analogues that are more efficacious and devoid of inverse agonist properties.

PETER D. SUZDAK*
JOHN R. GLOWA*
JACQUELINE N. CRAWLEY*
ROCHELLE D. SCHWARTZ*
PHIL SKOLNICK†
STEVEN M. PAUL*
**Clinical Neuroscience Branch, National Institute of Mental Health, Bethesda, MD 20892*, and
†Section on Neurobiology, Laboratory of Bioorganic Chemistry, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD 20892

REFERENCES AND NOTES

1. G. Kolata, *Science* **234**, 1198 (1986); Associated Press, *New York Times*, 28 November 1986, p. A23; J. Hammer, *Esquire* **106** (No. 6), 218 (December 1986).
2. E. P. Bonetti, W. P. Burkard, M. Gabl, H. Mohler, *Br. J. Pharmacol.* **86**, 463P (1985).
3. P. Polc *et al.*, *ibid.*, p. 465P.
4. P. D. Suzdak *et al.*, *Science* **234**, 1243 (1986).
5. H. Mohler, W. Sieghart, J. G. Richards, W. Hunkeler, *Eur. J. Pharmacol.* **102**, 191 (1984); W. Sieghart, A. Eichinger, J. G. Richards, H. Mohler, *J. Neurochem.* **48**, 46 (1987).
6. M. Corda, W. Blaker, W. Mendelson, A. Guidotti, E. Costa, *Proc. Natl. Acad. Sci. U.S.A.* **80**, 2072 (1983); J. R. Glowa, P. Skolnick, S. M. Paul, *Eur. J. Pharmacol.* **129**, 39 (1986).
7. S. E. File, in *Pharmacology of Benzodiazepines*, E. Usdin, P. Skolnick, J. Tallman, D. Greenblatt, S. M. Paul, Eds. (Macmillan, London, 1982), pp. 355–364; P. Skolnick, G. Reed, S. M. Paul, *Pharmacol. Biochem. Behav.* **23**, 17 (1985).
8. N. R. Oakley and B. J. Jones, *Neuropharmacology* **21**, 587 (1982); C. Braestrup, R. Schmiechen, G. Neff, M. Nielsen, E. Peterson, *Science* **216**, 1241 (1982).
9. M. Schweri *et al.*, *Life Sci.* **33**, 1505 (1983).
10. P. D. Suzdak, S. M. Paul, J. N. Crawley, in preparation.

Erratum: In the Technical Comment "*Trans*-activator gene of HTLV-II: Interpretation" by W. C. Greene *et al.* (27 Feb., p. 1073), the third-from-the-last sentence should have read, "In addition, using Jurkat or other T-cell lines, Inoue and colleagues (*2*) and Maruyama *et al.* (*3*) have described activation of both the IL-2 receptor and IL-2 genes by the *tat*-I gene isolated from HTLV-I, which shares similar structural and functional properties with the *tat*-II gene." Reference 3 should have been to M. Maruyama *et al.*, *Cell* **48**, 343 (1987).